| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 325,272 | 303,016 | ||
| Accounts receivable, net | 196,507 | 198,825 | ||
| Inventories, net | 23,774 | 18,441 | ||
| Prepaid and other current assets | 19,789 | 16,338 | ||
| Total current assets | 565,342 | 536,620 | ||
| Equipment, net | 605 | 667 | ||
| Right-of-use asset - operating lease | 21,654 | 22,472 | ||
| Goodwill | 12,042 | 12,042 | ||
| Intangible asset, net | 42,126 | 43,733 | ||
| Non-current inventory and other assets | 27,481 | 24,251 | ||
| Total assets | 669,250 | 639,785 | ||
| Accounts payable | 54,227 | 91,628 | ||
| Accrued expenses and other current liabilities | 225,632 | 170,902 | ||
| Operating lease liability, current portion | 736 | 337 | ||
| Contingent consideration, current | 9,695 | 9,232 | ||
| Short-term borrowings | 70,000 | 70,000 | ||
| Total current liabilities | 360,290 | 342,099 | ||
| Contingent consideration, non-current | 89,870 | 79,655 | ||
| Loan payable, long-term | 117,642 | 117,540 | ||
| Operating lease liability, long-term | 23,041 | 23,624 | ||
| Finance lease liability, long-term | 4,680 | 3,792 | ||
| Total liabilities | 595,523 | 566,710 | ||
| Common stock, 0.0001 par value per share (150,000,000 shares authorized, 50,307,834 and 48,667,587 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively) | 5 | 5 | ||
| Additional paid-in capital | 1,351,124 | 1,303,243 | ||
| Accumulated deficit | -1,277,402 | -1,230,173 | ||
| Total stockholders equity | 73,727 | 73,075 | ||
| Total liabilities and stockholders equity | 669,250 | 639,785 | ||
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)